A study of the efficacy of a combination of chlorambucil and lomustine and etoposide (CLE 56) for absolute refractory prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN50615178

Enrollment

Registered

2003-09-12

Start date

2003-02-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer Cancer Prostate cancer

Interventions

Chlorambucil, lomustine and etoposide (CLE 56). If one response is seen amongst the first 14 patients the target will be increased to 23. If one or more response is seen, consideration will be given

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Not provided at time of registration

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
1. To establish response rates and time to treatment failure of the regime CLE 56 2. To assess quality of life (QOL) 3. To establish effect on survival 4. To establish whether a hormone-free interval during chemotherapy leads to re-induction of endocrine therapy	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026